Clinical Trials Logo

Carcinoma, Islet Cell clinical trials

View clinical trials related to Carcinoma, Islet Cell.

Filter by:

NCT ID: NCT00093782 Completed - Clinical trials for Metastatic Gastrointestinal Carcinoid Tumor

Temsirolimus in Treating Patients With Metastatic Neuroendocrine Carcinoma

Start date: December 2003
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well CCI-779 works in treating patients with progressive metastatic neuroendocrine tumors. Drugs used in chemotherapy, such as CCI-779, work in different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00084461 Terminated - Insulinoma Clinical Trials

Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

Start date: March 2004
Phase: Phase 2
Study type: Interventional

Phase II trial to study the effectiveness of romidepsin in treating patients who have locally advanced or metastatic neuroendocrine tumors. Drugs used in chemotherapy, such as romidepsin, work in different ways to stop tumor cells from dividing so they stop growing or die.

NCT ID: NCT00075439 Completed - Insulinoma Clinical Trials

Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors

Start date: December 2003
Phase: Phase 2
Study type: Interventional

This phase II trial is studying how well gefitinib works in treating patients with progressive metastatic neuroendocrine tumors. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.

NCT ID: NCT00004074 Completed - Clinical trials for Fallopian Tube Cancer

Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu

Start date: August 1999
Phase: Phase 1
Study type: Interventional

Interleukin-12 may kill tumor cells by stopping blood flow to the tumor and by stimulating a person's white blood cells to kill cancer cells. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Phase I trial to study the effectiveness of interleukin-12 and trastuzumab in treating patients who have cancer that has high levels of HER2/neu and has not responded to previous therapy

NCT ID: NCT00003514 Withdrawn - Clinical trials for Merkel Cell Carcinoma

Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic or Unlikely to Respond to Surgery or Radiation Therapy

Start date: n/a
Phase: Phase 2
Study type: Interventional

RATIONALE: Antineoplastons are naturally-occurring substances that may also be made in the laboratory. Antineoplastons may inhibit the growth of cancer cells. PURPOSE: This phase II trial is studying how well antineoplaston therapy works in treating patients with neuroendocrine tumor that is metastatic or unlikely to respond to surgery or radiation therapy.